In 2020, these R & D areas deserve the attention of pharmaceutical companies

[pharmaceutical network industry trends] a few days ago, pharmaceutical executive released its 2020 Pipeline Report This is the 16th annual R & D pipeline report released by the company This report reviews the R & D pipeline in many R & D fields Today, based on the above report and the industry's hot research and development projects, the author will sort out for you what research and development fields are worth the attention of pharmaceutical companies in 2020 There are data showing that more than 3300 cells and gene therapy (CGT) are in the phase 2 to phase 4 clinical development stage, which shows that the research and development activities in this field are extremely active CGT can be used to treat many diseases including cancer, hemophilia, Huntington's dance, sickle cell anemia and so on Some people in the industry predict that great progress will be made in 2020, including BioMarin's new drug BMN-270 for the treatment of hemophilia type A; Sarepta's gene therapy for DMD; and a number of companies developing cancer CAR-T treatment, including Bristol Myers Squibb, Gilead, etc At present, this personalized therapy is being affirmed by regulators and payers, and will maintain a good trend in the future Cardiovascular drugs will become new battlefields With the increase of cardiovascular diseases, the incidence rate and mortality of cardiovascular diseases will be reduced It has become an increasingly urgent public health problem According to the Centers for Disease Control and Prevention (CDC), cardiovascular disease (CVD) is still the main cause of death for men and women In 2019, the number of cardiovascular and cerebrovascular patients in China has reached 290 million Among them, 13 million stroke, 11 million coronary heart disease, 5 million pulmonary heart disease, 2.5 million rheumatic heart disease, 2 million congenital heart disease and 270 million hypertension At present, hypertension, high cholesterol and smoking are the key risk factors of CVD Although there are many approved therapies for high blood pressure, high cholesterol and the factors that lead to CVD disease, researchers are still opening up a "new battlefield" for CVD treatment According to statistics, hypertension, congestive heart failure, and atherosclerosis are the indications of more preclinical studies Nash (nonalcoholic steatohepatitis) is a kind of chronic liver disease with a wide distribution and a very high proportion of the population It is an important cause of end-stage liver disease and liver cancer (HCC) There are about 1 billion patients with NASH in the whole globe In western countries, about 1 / 4 of the population suffers from nonalcoholic fatty liver disease (NAFLD) or Nash In China, 35% of the physical examination population has fatty liver, about 200 million NAFLD / NASH patients, accounting for 10-20% of the total population This figure is expected to increase significantly in the next 10 years as the population and related metabolic diseases continue to grow In addition, data shows that in the future, the global sales of Nash drugs may exceed 40 billion US dollars At present, there is no approved therapeutic drug for NASH in the world However, many enterprises have entered the phase II / III clinical stage It is believed that there will be new drugs for NASH in the near future, and the situation of no drug available for NASH will be alleviated But in this process, it is not known who will win In recent years, the research and development of new drugs for Alzheimer's disease has been very active in the past ten years, but the promising clinical results of these inputs and outputs are very few Since the discovery of Alzheimer's disease more than 100 years ago, only 3% of the 1141 drugs in the global treatment of Alzheimer's disease have entered phase III clinical, and only 1% of them have been successfully marketed; 68.4% of them are in no progress or termination state In the past 20 years, the world's major pharmaceutical companies have invested hundreds of billions of dollars in the research and development of new Alzheimer's disease treatment drugs, and more than 320 drugs entering clinical research have failed But at the end of last year, two pieces of news began to rekindle expectations for Alzheimer's treatment In October last year, Bojian and Weicai decided to submit to the FDA this year the application for approval of biological products (BLA) of aducanumab, a monoclonal antibody targeting β - amyloid protein Then, in November last year, the China drug regulatory bureau conditionally approved the listing of Lvgu pharmaceutical's nine phase one (Ganlu Turner capsule), which is now on the market in major Chinese pharmacies At present, many domestic pharmaceutical enterprises have been engaged in this field, such as ad-35 and tablets of Haizheng pharmaceutical In December 2015, they began to recruit subjects in the first phase of clinical trials In October 2016, they also entered the second phase of clinical trials In addition, in 2016, the class 1.1 chemical new drug piperidolone of Guangzhou Institute of medicine and health of Chinese Academy of Sciences and Guangdong South China new drug creation company was approved for clinical trials, and several listed companies, such as Da'an gene, Zhongsheng pharmaceutical and dongyangyao, held the equity of Guangdong South China new drug creation company.